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Abstract
Background: This work aimed to explore the action of natural prodigiosin on both 
bacterial organisms and Trypanosoma cruzi cells.
Methods: Natural prodigiosin pigment was extracted and purified from cultures 
of Serratia marcescens. Two media, peanut broth and peptone glycerol broth, both 
recommended in the literature for prodigiosin production, were compared. The 
prodigiosin obtained was employed to explore its antimicrobial properties against 
both bacteria and Trypanosoma cruzi cells. 
Results: Peanut broth yielded four times more prodigiosin. The prodigiosin showed 
remarkable activity (minimal inhibitory concentrations in the range of 2-8 µM for 
bacteria and half maximal inhibitory concentration of 0.6 µM for Trypanosoma cruzi). In 
fact, the prodigiosin concentration required to inhibit parasite growth was as low as 0.25 
mg/l versus 4.9 mg/l of benznidazole required. Furthermore, atomic force microscopy 
revealed marked morphological alterations in treated epimastigote forms, although no 
pore-formation activity was detected in protein-free environments. 
Conclusions: This work demonstrates the potential usefulness of prodigiosin against 
some gram-positive and gram-negative bacteria and Trypanosoma cruzi although further 
studies must be done in order to assess its value as a candidate molecule.
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Background
Prodigiosin is a linear tripyrrol produced as a secondary 
metabolite by different bacteria, including Serratia marcescens, 
Vibrio spp., Pseudomonas spp. and Streptomyces spp., among 
others [1]. It is a highly stable pigment, and a member of the 
alkaloid family called prodigionines, presenting a blood-red 
color at acidic pH values. Its synthesis is closely related to 
amino-acid metabolism [2,3]. Although its biological role in 
the producer microorganisms has not yet been elucidated, 
it has demonstrated a high electron transport capacity. 
Prodigiosin is capable of uncoupling H+/Cl− transporters, 
since it can bind to and transport chloride; subsequently, it 
modulates the pH of the bacterial cell [4]. Notwithstanding 
the scarce knowledge of its mechanism of action, prodigiosin 
appears as a pluripotent molecule, with various health-related 
properties; the most important being: an anticancer agent [5,6], 
an immunosuppressant, an antiprotozoal and an antibacterial 
agent, while also offering protection against UV [7,8,9]. 
Different studies have shown that prodigiosin inhibits the 
growth of a broad spectrum of gram-positive (Staphylococcus 
spp., Bacillus spp., etc.) as well as gram-negative (Escherichia 
coli, Salmonella enterica, etc.) bacteria [10]. Its capacity to 
inhibit the growth of eukaryotic microorganisms such as 
fungi (Candida albicans) and protozoa (Plasmodium spp. and 
Trypanosoma spp.) has also been reported [11,12,13]. 
The first report of the in vitro effect of prodigiosin on 
Trypanosoma cruzi dates from more than 65 years ago [14] 
when concentrations as low as 3 µM showed the capacity to 
completely inhibit the parasite. Azambuja et al. [15] reported 
interactions between Trypanosoma cruzi and a producer of 
prodigiosin, namely Serratia marcescens. Moreover, those authors 
succeeded in demonstrating that the loss of trypanosomal 
activity of Serratia marcescens DB11 was concomitant with 
the loss of capacity to produce prodigiosin, thereby indicating 
that the tripyrrolic pigment is a significant contributor to anti-
trypanosomal activity. Furthermore, the eventual usefulness of 
prodigiosin in the treatment of Chagas disease has been explored. 
Genes et al. [16] indicated that the activity of prodigiosin may 
mediate an apoptotic phenomenon in Trypanosoma cruzi by 
induction of mitochondrial dysfunctions. Finally, prodigiosin 
and another bacterial pigment (violacein from Chromobacterium 
violaceum), as well as their combinations with silver and gold 
nanoparticles, have been studied for their in vitro inhibition 
of the growth of Plasmodium falciparum and Trypanosoma 
brucei [17,18]. Prodigiosin was found to be more effective 
than violacein at inhibiting both of these parasites; moreover, 
combinations of prodigiosin and metal nanoparticles resulted 
in increased parasiticidal activity, while toxicity for mammalian 
cells remained stable.
Nevertheless, the antimicrobial properties of prodigiosin 
have often been questioned, particularly because of the high 
concentrations required for it to be effective, as these exceed the 
levels causing toxicity in mammalian cells. For this reason, it 
has been studied in greater depth for its use in anticancer and 
immunosuppressive therapy, than as an agent to fight infectious 
agents [19,20]. 
The interest in prodigiosin as a drug is clearly demonstrated by 
the number of reports in the literature from the different fields 
concerned, as well as by the explorations of its complexation 
and encapsulation, for both drug-delivery and to enhance its 
activity [21]. 
Our group has acquired considerable expertise in dealing 
with not only the physiology and properties of prodigiosin but 
also its production by Serratia marcescens. We are specifically 
interested in the antimicrobial activity of prodigiosin, including 
its antitrypanosomal activity [6,15,16]. 
In the present study, we focused our efforts on purifying 
crude extracts of bacterial origin and determining their activity 
against the parasite, in the hope of lowering the concentration 
needed to inhibit growth of the parasite, as well as decreasing 
its toxicity to mammalian cells. 
We compared two methods of prodigiosin production by 
evaluating the effect of peanut broth and peptone/glycerol broth 
on production of the pigment [22]. We also considered extraction 
methods by using organic solvents and setting up a purification 
system using an X-5 resin-affinity chromatography column [23] 
to purify the molecule in order to test whether such a procedure 
can increase its effectiveness at reducing toxicity.
Therefore, the present work aimed to explore and compare the 
action of the prodigiosin obtained on both bacterial organisms and 
Trypanosoma cruzi cells. In the case of the parasite, prodigiosin 
action was studied by determination of its anti-epimastigote 
activity, as well as by visualization of injuries and measurements of 
cell damage by atomic force microscopy (AFM). Furthermore, we 
have investigated the eventual alterations induced in membranes 
by the pigment through electrophysiological measurements of 
the conductance capacity in black lipid bilayers and by searching 
for channel forming activity. 
Methods
Bacterial strains and cultures
The following bacterial strains were used to measure 
susceptibility: Staphylococcus aureus ATCC 29213, and ATCC 
700698, Enterococcus faecalis ATCC 29212, Escherichia coli 
ATCC 25922, Pseudomonas aeruginosa ATCC 27853, plus one 
isolate of Bacillus subtilis and one of B. pumilus, from our own 
collection. They were thawed and maintained by daily passage 
in Columbia Blood Agar until the experiments were performed. 
Serratia marcescens 2170 was used as the prodigiosin producer. 
Parasite culture
For Trypanosoma cruzi CL-B5 maintenance, epimastigotes were 
cultured axenically at 28°C in liver infusion-tryptose medium 
(LIT; DifcoTM BD, MD, USA; Conda Pronadisa, Madrid, Spain) 
supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Gibco, Life Technologies, AU, NZ) plus antibiotics (100 μg 
streptomycin sulfate/ml and 100 U penicillin G sodium salt/ml, 
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SP; Sigma Aldrich, CA, USA). The CL-B5 strain was maintained 
in exponential growth by weekly passages [24,25].
Prodigiosin preparation
For prodigiosin production, Serratia marcescens 2170 was 
cultured overnight in peptone-glycerol medium under orbital 
shaking (250 rpm) at 30oC. Then, 75 ml of bacterial culture was 
spread onto peptone-glycerol agar and incubated for 48 hours at 
28oC. After incubation, the bacteria were harvested by scraping 
the plate surfaces, suspended in methanol:HCl (24:1 v/v), and 
centrifuged (8,000 x g for 15 min) to eliminate debris. The pigment 
was then collected and concentrated in a rotary evaporator. These 
prodigiosin preparations were denominated PG 1. 
In addition, after overnight culture in peptone-glycerol 
medium, Serratia marcescens 2170 was transferred to 1 l 
Erlenmeyer flasks (2.5 ml/l) and incubated for 72 h at 28oC in 250 
ml of peanut medium at 250 rpm. The peanut medium consisted 
of 2% crushed peanut seeds in distilled water, autoclaved at 
121oC for 20 min. The bacteria were centrifuged (8,000 x g for 15 
min), washed twice and finally the pigment was extracted using 
a mixture of methanol:HCl (24:1 v/v), and shaken overnight at 
250 rpm. After centrifugation to eliminate debris, the pigment 
was collected and concentrated in a rotary evaporator. These 
prodigiosin preparations were called PG 2. 
In another batch of production, the supernatants from both of 
the previous media were collected and purified by the technique 
described by Wang et al. [23], with some modifications, as we did 
not use raw material but rather previously extracted prodigiosin.
After the X-5 resin had been hydrated (in MilliQ water), the 
column was packed and washed successively with water to 
remove impurities. A layer of sand was added above the packed 
column, and then the pigment solution was poured into the 
column. Elution was carried out with methanol and colored 
fractions were collected.
Purified prodigiosin produced from the peptone-glycerol 
medium was denominated PG 3; and the purified prodigiosin 
produced from the peanut medium was called PG 4.
The purified prodigiosin was evaluated using: spectrophotometric 
analysis with absorbance determined in the range 450-700 nm; 
thin-layer chromatography (TLC); and electrospray ionization 
mass spectrometry ESI-MS. The prodigiosin concentration was 
calculated using the Beer-Lambert law, considering a value for 
the molar extinction coefficient of 110,000 M-1·cm-1 and using 
the maximum 535 nm absorbance value. 
Antibacterial effect
Values of minimal inhibitory concentration (MIC) were 
determined by the broth microdilution method and interpreted 
according to the EUCAST guidelines. Briefly, an isolate of each 
bacterial strain was grown at 37 °C and 250 rpm overnight in 20 
mL of Tryptic Soy Broth medium. Next, 800 µL of the culture 
was utilized to inoculate 20 m L of Mueller-Hinton medium. 
After 2h at 37°C and 250 rpm, bacterial inocula were adjusted 
with Ringer up to an optical density at 625 nm from 0.08 to 0.1 
(0.5 McFarland; 107-108 ufc/m L). Five (5) µL of each bacterial 
culture was added to a 96-well microplate previously filled with 
serial dilutions of prodigiosin. The plates were incubated at 37°C 
for 24 h. The MIC was determined macroscopically, by assessing 
turbidity with the aid of a mirrored viewbox, scoring the lowest 
concentration well without turbidity. Growth and control wells 
were also included. Each concentration was run in triplicate 
and the experiments were repeated three times independently.
Epimastigote susceptibility
Seven-day-old culture epimastigotes (2.5 x 105 /ml) were 
incubated in 96-well microplates (WWR Int LLC) with serial 
dilutions of natural prodigiosins for 72 hours at 28°C. Growth 
and control wells with only the parasite and the reference drug 
benznidazole (ELEA, Buenos Aires, Argentina), respectively, 
were also included in the assay. Each concentration was run 
in triplicate and the experiments were repeated three times 
independently. Parasite growth was checked by cell counting 
in a Neubauer chamber. 
The efficacy of the compounds was calculated by determining 
the epimastigote percentage growth, as follows: 
[(CD3t − CD0) / (CD3c − CD0)] × 100
where CD3t is the epimastigote concentration of treated parasites 
at day 3; CD0 is the epimastigote concentration at day 0; and 
CD3c is the epimastigote concentration of untreated parasites 
at day 3 [26]. 
The IC50 values (half maximal inhibitory concentration) were 
calculated using GraphPad Prism software.
Atomic Force Microscopy (AFM)
Since the activity of prodigiosin against microorganisms is 
attributed to plasma-membrane damage [27], we explored the 
effect of prodigiosin on epimastigote forms of Trypanosoma 
cruzi using AFM, by comparison between treated and untreated 
parasites. These alterations were also compared with those 
induced by the benznidazole treatments. 
Epimastigote forms of T. cruzi (CLB strain) cultivated 
in LIT medium, after exposure to prodigiosin 1.26 µM and 
benznidazole 48 µM for 72 h, were visualized using an XE-70 
atomic force microscope (Park Systems, Korea). We used these 
two concentrations [2 times 50% inhibitory concentration value 
(IC50)] since, although the parasite loses the capacity to grow, it 
is not completely destroyed and it is still feasible for visualizing 
organism surfaces and injuries. The parasites were collected by 
centrifugation, washed in phosphate buffered saline (PBS) 0.1 M, 
fixed with glutaraldehyde 2.5% in PBS 0.1 M for 1 hour, washed 
twice with 5 ml of MilliQ water and placed onto a MICA surface, 
allowed to dry at room temperature and then imaged in air using 
the AFM equipment. All images were collected in non-contact 
mode using pyramidal-shaped silicon cantilevers with a spring 
constant of ±40 N/m and a resonance frequency of ±300 kHz, 
with the upper side coated with aluminum to enhance the laser 
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beam reflectivity. The data acquired during the surface scanning 
were converted into images of topography and amplitude, and 
analyzed using XEP and XEI software (Park Systems, Korea). 
In the topography images, it was possible to observe the shape, 
structure, and surface of individuals. Furthermore, amplitude 
images enabled visualization of fine surface details. The AFM 
images were acquired with a scan size of 20 μm2 at a scan rate 
of 0.3–0.6 Hz. AFM was also employed to measure the surface 
roughness of the treated and untreated individuals. The roughness 
average (Ra), defined as the average distance from the roughness 
profile to the center plane of the profile, was calculated from the 
topography images obtained in these experiments. 
Statistical analysis
Both height and surface nano-roughness averages of the parasite 
cells after treatment with prodigiosin and benznidazole were 
compared and statistically analyzed by one-way ANOVA and 
Tukey’s test. Differences were considered significant when p < 0.05. 
Lipid bilayer experiments
The eventual channel-forming activity was explored via 
preparation of artificial lipid bilayers and the subsequent addition 
of prodigiosin. The black lipid bilayer experiments were carried 
out via the method reported by Benz et al. [28]. Membranes were 
formed by forming a 0.8 mm2 hole in a divider separating two 
compartments of the Teflon chamber containing 5 mL each 
of a bathing solution of salt, with 1% (w/v) lipid diphytanoyl 
phosphatidylcholine solution in n-decane (Avanti Polar Lipids). 
All salts (analytical grade) were obtained from Sigma Aldrich, 
Spain. Voltages were applied across the membrane formed 
via Ag/AgCl electrodes connected by a salt bridge, and the 
resultant current was boosted by a factor of 109–1010 by a current 
amplifier, and recorded on a Rikadenki strip chart recorder. The 
temperature was maintained at 20oC throughout. 
In order to evaluate channel-forming activity, increasing 
volumes of PG 3, starting at 1 μl and arriving at a final volume of 
50 μl, were added to the aqueous phase of both sides of the bilayer, 
until a final concentration of 0.44 μM was reached on each side. 
For PG 4, after the addition of increasing volumes, starting at 
1 μl and arriving at a final volume of 50 μl, we achieved a final 
concentration of 0.94 μM on each side. 
Results
Prodigiosin production
Both methods employed to produce prodigiosin to perform the 
further experiments yielded apparently clean pigment solutions 
that were relatively pure and adequate for the experiments. 
However, the pigment yield when bacteria were cultured in 
peanut broth was much higher, as shown in Table 1. In all cases, 
purity was determined and proven to be acceptable, as can be 
concluded from Figure 1, which shows absorption spectra with 
the typical peak at 535 nm and a shoulder at 515 nm; while no 
other peaks or disturbances were observed. Mass spectrometry 
confirmed the results (data not shown). 
Table 1. Preparation of prodigiosin for experimental determination of antitrypanosomal and antibacterial action.
Prodigiosin 
preparation code Medium Extraction Purification
Final prodigiosin 
concentration (µM)
PG 1 Peptone-glycerol Methanol: HCl (24:1) ND 42
PG 2 Peanut Methanol: HCl (24:1) ND 160
PG 3 Peptone-glycerol Methanol: HCl (24:1) X-5 Resin 44
PG 4 Peanut Methanol: HCl (24:1) X-5 Resin 177
ND: not done
Antibacterial effect
Purified prodigiosin preparations (PG 3 and PG 4) displayed 
remarkable antimicrobial activity, as can be concluded from the 
MIC values (Table 2) against all the bacterial strains tested, which 
represented the major groups of pathogenic microorganisms 
except Mycobacterium. 
Table 2. MIC of prodigiosin against the different bacterial strains tested.
Bacterial strain MIC (μM)
S. aureus ATCC 29213 4
S. aureus ATCC 700698 4
B. subtilis 2
B. pumilus 2
E. faecalis ATCC 29212 2
E. coli ATCC 25922 2
P. aeruginosa ATCC 27853 8
MIC: minimal inhibitory concentration 
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Epimastigote susceptibility
Similarly, the preparations were highly active against parasites 
in the epimastigote state (Fig. 2). Table 3 shows values of anti-
epimastigote activity (IC50). Activity of both chromatographically 
purified prodigiosin preparations gave lower IC50 values than 
those in a native state (just extracted, without purification). The 
value for the drug currently utilized to treat Chagas disease 
(benznidazole) is also reported, to facilitate comparison. 
Figure 1. Visible adsorption spectra (range: 450-700 nm) of purified prodigiosin obtained from peptone-glycerol medium (A) and peanut broth (B).
Figure 2. Biological activity of benznidazole and prodigiosin preparations against T. cruzi epimastigotes of the CL-B5 strain expressed as percentage of growth 
with corresponding standard deviation.
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Table 3. Biological activity of natural, extracted and purified prodigiosin preparations against T. cruzi epimastigotes (CL strain, clone B5).






IC50 50% inhibitory concentration
AFM
Epimastigote forms of T. cruzi treated with prodigiosin (PG 3) 
showed severe morphological alterations with loss of membrane 
integrity, as can be concluded by observing the corresponding 
images (Figure 3). Moreover, several parameters were affected 
after treatment, such as average height of the parasite cell 
(Figure 4 a) and surface nano-roughness (Figure 4 b).
Lipid bilayer experiments 
When the extracts of prodigiosin (PG 3 and PG 4) were added 
to bathing solutions separated by black lipid bilayer membranes, 
no significant increases in conductance were observed. This 
indicates that, at least in lipid bilayers constructed in our 
laboratory, the incorporation of prodigiosin into the bilayer, 
when it happened, did not lead to formation of transmembrane 
channels at any of the concentrations assayed in our experiments. 
We conclude that there was no pore-forming activity of 
prodigiosin in protein-free environments.
Discussion
Prodigiosin production was compared between the two media 
used (peptone-glycerol medium and peanut broth), revealing 
that peanut medium yields much more pigment (up to fourfold 
more) as shown in Table 1. Thus, when the goal is to produce 
natural prodigiosin, peanut broth would be efficacious. Our 
results confirm (and optimize) those reported by Giri et al. [22]. 
All four prodigiosin preparations obtained from S. marcescens 
2170 cultures exhibited a marked antibacterial effect, similar 
to that already reported by other authors [27]. We obtained 
evidence that biological features of the prodigiosin obtained in 
our laboratory were maintained during the different extraction 
and purification procedures. When measuring antitrypanosomal 
action, there were no differences due to the media used in the 
production step (peptone-glycerol medium and peanut broth): the 
antitrypanosomal action was identical. Moreover, purification 
using X-5 resin increased antitrypanosomal effectiveness. This 
may be attributed to a higher purity level and the subsequent 
Figure 3. AFM amplitude images obtained at a 20 μm2 scan size, of: (A) untreated T. cruzi epimastigotes; (B) T. cruzi epimastigotes after 72 h of treatment with 
PG 3, 1.26 µM; (C) T. cruzi epimastigotes after 72 h of treatment with benznidazole, 48 µM.
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absence of interfering remains of bacteria and debris. In fact, 
when comparing the data, we can conclude that the benznidazole 
concentrations required to inhibit parasite growth are clearly 
higher than those needed with prodigiosin (4.9 mg/l and 0.25 
mg/l, respectively). 
When the capacity of prodigiosin to form channels was 
explored, our measurements did not indicate any insertion 
into the artificial membranes created. That is to say, no increases 
in conductance were detected. In principle, the addition of 
an ion transporter into a membrane should result in discrete 
increases of conductance; the lack of positive results may be 
a consequence of an incapacity of the molecule to become 
inserted into the bilayer. It has been shown that prodigiosin is 
a molecule that resides in bacterial membranes [29], while its 
antimicrobial action has been attributed to membrane injuries 
[27], which is apparently inconsistent with its failure to modify 
the membrane conductance observed herein. Nevertheless, 
artificial black lipid bilayers, despite acting electrophysiologically 
as cell membranes, are formed only by lipids and we cannot 
rule out the possibility that insertion of the prodigiosin, and 
its activity as an ion transporter, may require the cooperation 
of some membrane protein or some special domains of lipids 
other than the ones used in building artificial bilayers. 
The effect of prodigiosin against gram-positive and gram-
negative bacteria that we found is remarkable.
As to trypanocidal activity, the IC50 values of the purified 
prodigiosin preparations were more active than crude ones, 
probably due to the purity of their composition.
The action mechanism of prodigiosin as an antimicrobial agent 
is not fully established, although the acquired AFM images of 
treated epimastigotes showed remarkable changes on parasite 
cell surfaces as well as in height and roughness, suggesting a 
catastrophic scenario caused by the pigment. This is consistent 
and complements the results of Genes et al. [16] when reporting 
the activity of prodigiosin against T. cruzi, evidencing that 
the mode of action of prodigiosin involves the mitochondrial 
function. In fact, despite using different strains ( TcI and TCII) 
with different susceptibilities to Benznidazole, they found that 
classical inhibitors of respiratory function such as Rotenone, 
Thenoyltrifluoroacetone (TTFA), potassium cyanide (KCN) and 
antimycin A, produce an effect on mitochondrial membrane 
potential similar to that of prodigiosin, but they were much less 
parasiticidal. Thus, it may be plausible that prodigiosin action 
takes place not only on mitochondria, but also in other cell 
compartments and mainly on plasma membrane. 
In conclusion, the findings of the present study strongly 
indicate that prodigiosin exerts a potent action by killing T. 
cruzi in its epimastigote form. These findings suggest that the 
bacterial secondary metabolite could become a resource in 
fighting Chagas disease. Therefore, additional studies need to 
be performed to verify its safety in relation to mammalian cells 
and intracellular and trypomastigote forms of the parasite.
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